HOUSTON, Aug. 16, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that Dr. Michael Kaminer
presented and discussed the company's Rapid Acoustic Pulse
technology ("RAP") for the treatment of cellulite at the
Controversies and Conversations Symposium, August 9-11, 2019 in San Francisco.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
Dr. Kaminer presented the audience of practicing dermatologists
and plastic surgeons an overview of the "acoustic subcision"
generated by RAP treatments. He discussed the dose ranging
effect with RAP indicating an increased effect from longer
treatments with the device. He explained that subcision of
the hardened septa is the most effect way to eliminate the dimples
and ridges associated with cellulite.
Dr. Chris Capelli, President, CEO
and co-founder of Soliton, commented, "Dr. Kaminer is one of three
founding physicians at SkinCare Physicians in Chestnut Hill,
MA. He is one of our country's preeminent dermatologists,
cosmetic surgeons and researchers. He chairs the Soliton
Scientific Advisory Board and has led multiple clinical trials
exploring the use of our RAP technology. We are honored to
have Michael present his thoughts to the symposium attendees."
Dr. Kaminer stated: "Having led the clinical development of
Cellfina, the only treatment with FDA clearance for producing
long-term reduction of cellulite, I am particularly aware of the
unmet need in the treatment of cellulite. Having a non-invasive
alternative treatment with lasting results could provide a real
benefit for patients while also expanding the breadth of services
offered by clinicians."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton's
acoustic shockwave device to generate acoustic subcision and the
impact of acoustic subcision on cellulite. These statements relate
to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Soliton has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/dr-michael-kaminer-presented-soliton-rap-for-cellulite-at-key-dermatology-conference-300902862.html
SOURCE Soliton, Inc.